stoxline Quote Chart Rank Option Currency Glossary
Ventyx Biosciences, Inc. (VTYX)
2.96  -0.24 (-7.5%)    07-17 16:00
Open: 3.15
High: 3.17
Volume: 898,902
Pre. Close: 3.2
Low: 2.945
Market Cap: 209(M)
Technical analysis
2024-07-17 5:31:12 PM
Short term     
Mid term     
Targets 6-month :  3.97 1-year :  4.63
Resists First :  3.4 Second :  3.97
Pivot price 2.46
Supports First :  2.57 Second :  2.06
MAs MA(5) :  2.8 MA(20) :  2.47
MA(100) :  4.81 MA(250) :  11.63
MACD MACD :  -0.2 Signal :  -0.4
%K %D K(14,3) :  91.5 D(3) :  88.2
RSI RSI(14): 52.2
52-week High :  38.2 Low :  1.86
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VTYX ] has closed below upper band by 8.0%. Bollinger Bands are 60.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.17 - 3.19 3.19 - 3.2
Low: 2.91 - 2.93 2.93 - 2.94
Close: 2.93 - 2.96 2.96 - 2.98
Company Description

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

Headline News

Mon, 15 Jul 2024
Norden Group LLC Takes Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

Thu, 11 Jul 2024
Norden Group LLC Takes $59,000 Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

Sat, 06 Jul 2024
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth? - Yahoo Finance

Mon, 01 Jul 2024
Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade) (NASDAQ:VTYX) - Seeking Alpha

Tue, 25 Jun 2024
VENTYX STOCK ALERT: Ventyx’s (Nasdaq:VTYX) Board is Being - GlobeNewswire

Mon, 13 May 2024
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 71 (M)
Shares Float 52 (M)
Held by Insiders 3.1 (%)
Held by Institutions 94.4 (%)
Shares Short 7,950 (K)
Shares Short P.Month 8,310 (K)
Stock Financials
EPS -3.25
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.36
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -36 %
Return on Equity (ttm) -56.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.94
Qtrly Earnings Growth 0 %
Operating Cash Flow -183 (M)
Levered Free Cash Flow -110 (M)
Stock Valuations
PE Ratio -0.92
PEG Ratio 0
Price to Book value 0.67
Price to Sales 0
Price to Cash Flow -1.14
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android